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Abstract
Background: Chinese medicine xiangshaliujunzi decoction (XSLJZD) plays a key role in treating functional dyspepsia
(FD), a common clinical gastrointestinal disorder. However, the mechanism of this disease is unclear. Brain–gut axis
regulates food intake behaviour, and this regulatory mechanism is mediated by neuropeptides. Brain–gut axis impairment
and neuropeptide alteration may be the pathological mechanisms of FD, and brain–gut axis regulation may influence the
action of medicine.
Methods: In our experiment, the effect of XSLJZD on FD was evaluated in terms of food intake, sucrose preference test
and electromyogram. Changes in neuropeptides [ghrelin, cholecystokinin (CCK) and vasoactive intestinal polypeptide
(VIP)] were detected through immunohistochemistry, real-time PCR and ELISA.
Results: XSLJZD increased food intake and the percentage of sucrose preference (>75 %). However, the response to
gastric detention decreased. Furthermore, XSLJZD increased ghrelin, CCK, VIP proteins and genes in the stomach.
XSLJZD also increased ghrelin, CCK and VIP proteins in serum. By contrast, XSLJZD decreased the mRNA expression of
these neuropeptides in the hypothalamus.
Conclusions: XSLJZD alleviated the symptoms of FD by upregulating the production of ghrelin, CCK and VIP and by
increasing the levels of these neuropeptides in circulation. This finding can help elucidate the mechanism of FD and
can provide further insight into the pharmacokinetics of XSLJZD.
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Background
Functional dyspepsia (FD) is a common clinical gastro-
intestinal disorder characterised by persistent or recur-
rent pain and discomfort. This discomfort is mainly
experienced in the upper abdomen without evidence of
organic structural abnormalities associated with these
symptoms. In a household survey, approximately 25 %
of the normal population in the United States suffers
from FD [1]. In China, a definite statistics for FD is lack-
ing; however, several works indicate that 8.66 to 11 % of
patients opt for hospital admission because of abdominal
fullness [2–4]. A number of pathophysiological mecha-
nisms have been proposed to explain several clinical
symptoms, including hypersensitivity to gastric disten-
tion, impaired gastric accommodation of a meal, delayed
gastric emptying, altered duodenal sensitivity to lipids or
acid, abnormal duodenojejunal motility and central ner-
vous system (CNS) dysfunction; however, the evidence
related to these symptoms varies in patients [5, 6].
Hence, the definite mechanism remains unknown.
FD, an example of functional gastrointestinal disorders,
is a common pathological condition affecting the gut,
which is controlled by the nervous system [7]. The gastro-
intestinal tract (GIT) and the nervous system, including
CNS and enteric nervous system (ENS), are involved in a
two-way extrinsic communication by parasympathetic and
sympathetic nerves. These nerves contain efferent fibres
and afferent sensory fibres required for gut–brain signal-
ling. Afferent nerves comprise many sensors at the termi-
nals in the gut related to visceral mechano-, chemo-, and
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noci-receptors; when excited, these sensors may trigger
various visceral reflexes that regulate GIT functions, in-
cluding appetite [8–10]. The disorders affecting the regula-
tion of the two-way communication between the brain and
the gut (brain–gut axis) are important in the pathogenesis
of these diseases [11]. Neuropeptides are important media-
tors in the nervous system and between neurons and other
cell types. Neuropeptides, such as ghrelin, cholecystokinin
(CCK) and vasoactive intestinal polypeptide (VIP), are pos-
sibly implicated in the bidirectional gut–brain communica-
tion [12]. Ghrelin is a 28-amino acid peptide hormone
[13], which is produced predominantly by P/D1 cells of the
gastric oxyntic gland; this hormone is mainly found in the
proximal stomach [14, 15]. Ghrelin is involved in many
biological activities because this hormone plays autocrine
and paracrine roles in regulatory processes, such as
regulation of appetite, gut motility, growth hormone
release, immunomodulation [16, 17] and initiation of
food intake under neural control [18]. CCK belongs to
the gut–brain family of peptide hormones [19]. This
hormone is secreted by the gastrointestinal system in
response to food intake; furthermore, CCK is released
by specialised neurons in the myenteric plexus and the
brain [20]. In a previous study, intravenous injection of
CCK suppresses hunger and feeding in humans [21–23].
CCK also participates in signal transduction in the brain–
gut axis via the primary afferent fibres of the vagus nerve,
and the same fibres probably trigger the expression of re-
ceptors for ghrelin [24]. VIP, a 28-amino acid neuropep-
tide, is distributed in central and peripheral neurons; this
neuropeptide is involved in many physiological intestinal
functions, such as motility regulation, secretory activity
and vasodilatation, peristaltic reflex inhibition in the circu-
lar smooth muscle layer and sphincter relaxation [25].
Neuronal VIP is also a mediator of neural response to
aspirin-induced stomach inflammatory state [26]. These
studies demonstrated that the disorder of the brain–gut
axis may be the pathogenesis of FD.
Xiangshaliujunzi decoction (XSLJZD), a classic decoc-
tion used during Qing Dynasty in China, plays a key role
in the treatment of FD; XSLJZD is more effective than
prokinetic drugs in the treatment of this disease [27].
However, the mechanism by which XSLJZD relieves FD
remains unknown. We studied the mechanism of the
modified XSLJZD on the perspective of the brain–gut
axis and neuropeptides. This regulatory mechanism can
be the specific mode to treat FD.
Methods
Animals
Male Sprague–Dawley rats were used in all of the experi-
ments (SPF Laboratory Animal Technology Co., Ltd.,
Beijing, China). The experiments were performed in
accordance with the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of
Health (NIH Publications No. 85–23, revised 1996) and
with the approval of the Animal Care Committee of Beijing
Medical Centre. The 10-day-old rat pups received 0.2 mL
of 0.1 % iodoacetamide (IA) in 2 % sucrose by oral gavage
daily for 6 days. The control group received 0.2 mL of 2 %
sucrose [28]. The 6-week-old IA-treated rats were ran-
domly divided into four groups: model group (n = 12;
received same volume of water as vehicle), XSLJZD-treated
group (n = 12; treated with XSLJZD), low-dose XSLJZD-
treated group (n = 12; treated with half dose of XSLJZD)
and domperidone-treated group (n = 12). The 6-week-old
sucrose-treated rats were designated as the control group
(n = 12). The 6-week-old rats received 5 mL/kg of each
drug or water daily by oral gavage for 10 days.
Drugs
XSLJZD is composed of eight different Chinese medi-
cinal herbs (Table 1). The components were prepared
by the Pharmaceutical Department of Xiyuan Hospital,
affiliated with Chinese Academy of TCM. Pure extracts
of the components were prepared. The components
were dissolved in water. Half dose (12.5 mg/kg) and full
dose (25 mg/kg) of XSLJZD were administered to the
rats in the low-dose and XSLJZD-treated groups, re-
spectively. Domperidone (3 mg/kg Xian Janssen
Pharmaceutical Ltd.) was administered to the rats in the
domperidone-treated group. The full dosage of XSLJZD
administered to rats was converted from the dosage
administered to humans. Meanwhile, the model and
control groups received 5 mL/kg water daily by oral
gavage for 10 days.
Food intake measurement
Food intake was measured before and after the drug
treatment. After 18 h of fasting, the rats were housed in-
dividually. The food was provided for 7 h, and the food
consumption was calculated.
Sucrose preference test (SPT)
SPT [29–31] was conducted before and after the drugs were
administered to the rats. Before the test was performed, the
rats were treated to adapt to sucrose solution. In the train-
ing session, the rats were housed individually for 48 h in a
cage with two bottles; one bottle contained 1 % sucrose
solution, whereas the other bottle contained tap water. The
bottles were placed to the left side and to the right side of
the feeding compartment; the positions of these bottles
were switched at an interval of 12 h to prevent possible
effects of side preference in drinking behaviour. After the
training session was completed, only tap water was provided
for 6 h. Food and water were then withheld from the rats
for 18 h. In the test session, the rats were provided access to
two bottles containing 1 % sucrose solution and water for
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1 h. Sucrose preference (SP) was quantified with the follow-
ing equation: SP = [sucrose intake (g)]/[sucrose intake (g) +
water intake (g)]. The proportion of rats in each group with
an SP value of >75 % was counted and compared through
chi-square test.
Gastric balloon distensions for electromyographic (EMG)
testing [28]
After being subjected to overnight fasting, the rats were
anesthetised intraperitoneally with 1 % pentobarbital
sodium (3 mg/kg) after the drugs were administered for
10 days. Balloons (2.5 cm in length) made from latex
condoms were attached to a long catheter. An epigastric
incision was made, and the balloon was placed in the
stomach through an incision at the tip of the fundus. The
pylorus was not obstructed, and no blockage of gastric
emptying was observed. A polyethylene tubing to inflate
the gastric balloon with air was exteriorised at the back of
the neck. Electromyographic (EMG) studies were con-
ducted a week after surgery. Before the experiment, all the
animals were anesthetised intraperitoneally with 1 % pento-
barbital sodium (3 mg/kg). Then, a pair of stainless steel
wires was implanted into the acromiotrapezius (a superfi-
cial neck muscle) and externalised at the back of the neck
for EMG recordings.
In the experiment, the rats received a series of 20 s gastric
balloon distensions: 10, 20, 30, 40 and 50 mmHg (measured
with a sphygmomanometer) at an interval of 2 min
between distensions. A BL-420S biological and functional
experimental system was used to record EMG continuously
and to visualise data. EMG was corrected, and the area
under the curve was calculated for 20 s distension period.
The baseline activity, obtained 20 s before distension, was
subtracted from the EMG induced by distension. The data
Fig. 1 Food intake of each group. Food intake was lower in model
group compared with control group. In XSLJZD-treated group and
Domperidone-treated group, it was higher compared with model group. *
P<0.05 compared with the control group; ** P<0.01 compared with the
control group; △ P<0.05 compared with the model group; △△ P<0.01
compared with the model group. Data were presented as mean± SE
Fig. 2 Percentage of rats in each group with sucrose preference (SP)
value >75 %. The percentage of SP value >75 % in model group was
lower compared with control group. In XSLJZD-treated group and
Domperidone-treated group, the percentage was higher compared with
model group. ** P<0.01 compared with control group and △△ P<0.01
compared with model group by Chi-square test. Data were presented as
percentage of rats in each group with SP value of >75 %
Table 1 Components of the XSLJZD solution
Scientific name Part used Proportion of ingredients (100 %)
Astragalus mongholicus Root 12
Codonopsis pilosula Root 12
Rhizoma Atractylodis Macrocephalae Rhizome 12
Poria cocos Sclerotium 12
Fructus Aurantii Fruit 12
Amomum villosum Fruit 6.4
Ligusticum chuanxiong Hort. Sclerotium 9.6
Rhizoma corydalis Rhizoma 9.6
Medicated Leaven Fermentation products 12
Glycyrrhiza uralensis Fisch. Root 2.4
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Fig. 3 Electromyographic (EMG) response to gastric distention of rats in each group. a EMG response to gastric distention of each group at
distension of 10 mmHg to 50 mmHg. In XSLJZD-treated group, EMG was reduced significantly compared with model group at distension of 20 mmHg,
30 mmHg and 40 mmHg. ** P <0.01 compared with control group. Data were presented as mean ± SE. b Representative EMG response at 30 mmHg
of each group
Fig. 4 Expression of Ghrelin in hypothalamus of each group. a Control group. b Model group. c XSLJZD-treated group. d Low-dose XSLJZD treated
group. e Domperidone-treated group. Ghrelin distributed in cytoplasm of hypothalamus. (Tissue sections were viewed at 100× magnification.) Positive
cells for Ghrelin were brown and circular or pear-shaped. Fewer positive cells can be seen in the model group
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were presented as the change from the baseline as a func-
tion of distension pressure.
Immunohistochemistry
After 10 days of drug treatment, the rats were anes-
thetised with 1 % pentobarbital sodium. Brains and
stomachs were removed, fixed with 10 % formalin
and embedded in paraffin. The tissues were subse-
quently cut in 10 μm sections, mounted on Superfrost
Plus slides (1 section/slide) and stored at room
temperature. Before the experiment was conducted,
the slides were deparaffinised using xylene, subjected
to microwave heat-mediated antigen retrieval using
citrate buffer at pH 6 for 45 min and were cooled to
room temperature. The specimens were immersed in
3 % H2O2 for 20 min to inactivate endogenous perox-
idase and were subsequently washed with PBS (thrice
for 2 min each). The sections were incubated over-
night at 4 °C with the following antibodies: polyclonal
rabbit anti-ghrelin (1:100, Abbiotec), polyclonal rabbit
anti-VIP (1:20, Abcam) and polyclonal rabbit anti-
CCK-8 (1:100, Abbiotec) in buffer containing 0.01 M
PBS. By 9:00 a.m. the next day, the slides were
washed with PBS (thrice for 2 min each) and were in-
cubated in Polink-2 Plus® Polymer HRP Detection
System (ZSGB-BIO, Beijing) according to the manu-
facturer’s instructions. Afterwards, the sections were
washed thrice with PBS, visualised by using DAB for
10 min at 37 °C and rinsed with running water for
2 min. After dehydration, the slides were mounted
using neutral balsam. The sections were visualised
under a microscope, and images were acquired using
a camera. At least three sections per rat and three
rats per group were analysed. Mean integrated optical
density (MOD) was calculated using Image-Pro Plus
version 6.0 analysis software.
Real-time PCR
After 10 days of drug treatment, the rats were anesthetised
with 10 % chloral hydrate. The hypothalamus and stomachs
of these rats were removed. mRNA was quantified by using
quantitative RT-PCR. Total RNA was extracted from the
rats’ hypothalamus and stomach by using Promega SV total
RNA isolation system (Promega, USA) according to the
Fig. 5 Expression of CCK-8 in hypothalamus of each group. a Control group. b Model group. c XSLJZD-treated group. d Low-dose XSLJZD treated group.
e Domperidone-treated group. CCK-8 mainly distributes in cytoplasm of hypothalamus. (Tissue sections were viewed at 100× magnification.) Positive cells
for CCK-8 were brown and circular or oval-shaped. Fewer positive cells can be seen in the model group and low-dose XSLJZD-treated group
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manufacturer’s instructions. Total RNA (2 μg) was reverse-
transcribed by using PromegaGoScript (Promega, USA) ac-
cording to the manufacturer’s instructions. The thermocy-
cling conditions used are listed as follows: initial activation
at 95 °C for 30 s; 40 cycles of denaturation at 95 °C for 5 s,
annealing at 60 °C for 30 s; and melt curve determination
at 65 °C to 95 °C for 5 s. Primers were designed using
Primer-BLAST (NCBI, USA) according to the mRNA se-
quences (by GenBank) of ghrelin (NM_021669.2), VIP
(NM_053991.1), CCK (NM_012829.2) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; NM_017008.4, as
control). The PCR products were run on 0.8 % agarose gel
to confirm that these products were of the expected size.
Results were normalised against GAPDH expression. The
primer sequences are listed as follows. The forward and re-
verse primers of the GAPDH gene were 5′-GGCACAGT
CAAGGCTGAGAATG-3′ and 5′-ATGGTGGTGAAGAC
GCCAGTA-3′, respectively. The forward and reverse
primers of the ghrelin gene were 5′-CCAAGGCCAT
GGTGTCTTCA-3′ and 5′-CTGCAGTTTAGCTGG
TGGCTTC-3′, respectively. The forward and reverse
primers of the VIP gene were 5′-TCAGTTCCT
GGCGATCCTGAC-3′ and 5′-CTCCGCTAAGGCAT
TCTGCAA-3′, respectively. The forward and reverse
primers of the CCK gene were 5′-CCCGATACATC
CAGCAGGTC-3′ and 5′-AAATCCATCCAGCCCA
TGTAGTC-3′, respectively. 2-ΔΔCt was calculated, and
differences between groups were analysed by using
non-parametric tests.
ELISA
Rats were anesthetised with 10 % chloral hydrate after
10 days of drug treatment. Blood samples were col-
lected in blank sterile tubes and allowed to clot for
2 h at room temperature. Subsequently, these samples
were centrifuged at 1000 rpm for 15 min. Serum was
removed and stored at −80 °C. Ghrelin, VIP, and
CCK were quantified using specific ELISA kits sup-
plied by CUSABIO (Wuhan, China). Each serum
(100 μL) was mixed with sample diluent according to
the manufacturer’s instructions. Absorbance was de-
termined at 450 nm.
Fig. 6 Expression of VIP in hypothalamus of each group. a Control group. b Model group. c XSLJZD-treated group. d Low-dose XSLJZD treated
group. e Domperidone-treated group. Neuropepide VIP mainly distributes in cytoplasm of hypothalamus. (Tissue sections were viewed at 100×
magnification.) Positive cells for VIP were brown and circular or oval-shaped. Fewer positive cells can be seen in the model group and low-dose
XSLJZD-treated group and domperidone-treated group
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Data analysis
All values, except those obtained by sucrose prefer-
ence test, were presented as means ± SE. One-way
ANOVA or non-parametric test was conducted for
comparison. Post hoc comparisons were performed
using Student–Newman–Keuls test or Mann–Whitney
U test. Statistical analysis was performed in SPSS
17.0. P <0.05 was considered statistically significant.
Results
XSLJZD increased the food intake of the rats with FD
After overnight fasting, rats with FD consumed lesser
amount of food than the control rats during a 7 h period
(10.7 ± 0.6 vs. 8.7 ± 0.5; P = 0.01; n = 10 in each group). The
XSLJZD-treated group consumed greater amount of food
than the model group (10.7 ± 0.9 vs. 8.7 ± 0.5; P = 0.04; n =
10 in each group). Likewise, thedomperidone-treated group
consumed greater amount of food than the model group
(12.4 ± 0.7 vs. 8.7 ± 0.5; P = 0.00). No significant difference
was observed between the low-dose XSLJZD-treated group
and the model group (8.4 ± 1.2 vs. 8.7 ± 0.5; P > 0.1) (Fig. 1).
XSLJZD increased the percentage of sucrose consumption
(>75 %) of rats with FD
In the sucrose preference test, no significant difference was
observed in terms of sucrose and water intake among the
groups (P > 0.05). However, the percentage of rats with SP
value of >75 % was significantly reduced in rats with FD
(30 %) compared with the control rats (80 %; P = 0.001;
n = 10 in each group), as indicated by chi-square test. The
percentage significantly increased in the XSLJZD-treated
group (75 %) and in the domperidone-treated group (75 %)
compared with the rats with FD (30 %; P = 0.004; n = 10 in
each group). The low-dose XSLJZD-treated group did not
exhibit significant difference from the model group (Fig. 2).
XSLJZD reduced the hypersensitivity to gastric distention
of rats with FD
After the 10-day treatment, EMS testing was per-
formed. Compared with the control rats, rats with FD
significantly increased in EMG at distension pressures
of 20 mmHg (179.3 % vs. 282.5 %; P = 0.000; n = 3 in
each group), 30 mmHg (254.9 % vs. 420.1 %; P =
Fig. 7 Expression of Ghrelin in stomach of each group. a Control group. b Model group. c XSLJZD-treated group. d Low-dose XSLJZD treated group. e
Domperidone-treated group. Ghrelin was expressed as granular neuropetide in the cytoplasm of the stratum basale of the stomach (Tissue sections were
viewed at 20× magnification.) Brown cells were positive for Ghrelin. Model group expressed lower Ghrelin than control group, XSLJZD significantly increased
ghrelin of rats with FD
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0.000) and 40 mmHg (315.4 % vs. 412.3 %; P = 0.002).
However, no significant difference was observed at
50 mmHg. XSLJZD inhibited the EMG activity of rats
with FD to gastric distension in a dose-dependent
manner. XSLJZD elicited a significant effect at 20
(277.2 % vs. 282.5 %; P = 0.016), 30 (398.3 % vs.
420.1 %; P = 0.003) and 40 mmHg (405.5 % vs.
412.3 %; P = 0.015). Low dose significantly affected
EMG responses only at 30 (362.4 % vs. 420.1 %; P =
0.034) and 40 mmHg (353.3 % vs. 412.3 %; P = 0.038)
compared with the rats with FD, as indicated by one-
way ANOVA. Furthermore, the control group did not
significantly differ from the domperidone-treatment
group (P >0.1) (Fig. 3).
Expression of relative neuropeptides in the brain and the
stomach of each group
Ghrelin, CCK-8 and VIP were expressed as granular
neuropeptides in the cytoplasm of the hypothalamus
(Figs. 4, 5 and 6) and the stratum basale of the
stomach (Figs. 7, 8 and 9). The expressions of these
neuropeptides were lower in the brain and in the
stomach of rats with FD compared with those of the
control rats. In the stomach and the hypothalamus,
ghrelin, CCK-8 and VIP of the rats with FD were
lower than those of the control rats (P <0.05; n = 3 in each
group). Low-dose XSLJZD-treated groups did not signifi-
cantly differ from the model group. However, XSLJZD sig-
nificantly increased ghrelin, CCK-8 and VIP of rats with
FD (P <0.05; n = 3). Ghrelin, CCK-8 and VIP of the
domperidone-treated group were also higher than those
of the model group, except for VIP in the hypothalamus
(P <0.05; n = 3) (Table 2 and Fig. 10).
XSLJZD increased the neuropeptides in the serum of rats
with FD
Ghrelin was reduced in the serum of rats with FD
compared with that of the control rats (46.72 ± 4.92
vs. 189.9 ± 49.96; P = 0.007; n = 7 in each group). By
contrast, ghrelin was increased in the XSLJZD-
treated group compared with the model group
Fig. 8 Expression of CCK-8 in stomach of each group. a Control group. b Model group. c XSLJZD-treated group. d Low-dose XSLJZD treated group.
e Domperidone-treated group. CCK-8 mainly distributes in stratum basale of stomach. (Tissue sections were viewed at 20× magnification.) Positive
CCK-8 expressed as brown granule, distributed in cytoplasm. Expression of CCK-8 was lower in model group and low-dose XSLJZD-treated group,
higher in control group, XSLJZD-treated group and domperidone-treated group
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(186.4 ± 40.13 vs. 46.72 ± 4.92; P = 0.009; n = 7 in each
group). No significant difference was observed among
the control group, low-dose XSLJZD-treated group
and domperidone-treated group in terms of ghrelin
in the serum. Similar to ghrelin, CCK was reduced
in the serum of rats with FD compared with that of
the control rats (22.77 ± 3.59 vs. 77.19 ± 14.36; P = 0.003;
n = 7 in each group). CCK was increased by XSLJZD in a
dose-dependent manner. The low-dose XSLJZD-treated
groups did not significantly differ with the rats with FD in
Fig. 9 Expression of VIP in stomach of each group. a Control group. b Model group. c XSLJZD-treated group. d Low-dose XSLJZD treated group.
e Domperidone-treated group. VIP was expressed as granular neuropetide in the cytoplasm of the stratum basale of the stomach (Tissue sections
were viewed at 20× magnification.) Brown cells were positive for VIP. Expression of VIP was lower in model group and higher in control group,
XSLJZD-treated group and domperidone-treated group
Table 2 MOD value of relative neuropeptides in the stomach and hypothalamus of each group
Part Groups Ghrelin CCK-8 VIP
Stomach Control 0.583 ± 0.008 0.714 ± 0.042 0.823 ± 0.025
Model 0.368 ± 0.010** 0.467 ± 0.057* 0.486 ± 0.025**
XSLJZD 0.716 ± 0.050*△△ 0.706 ± 0.090△ 0.861 ± 0.107△△
Low dose XSLJZD 0.356 ± 0.044** 0.498 ± 0.039 0.652 ± 0.082
Domperidone 0.543 ± 0.163△△ 0.863 ± 0.122△△ 0.711 ± 0.092△
Hypothalamus Control 0.497 ± 0.036 0.825 ± 0.081 0.561 ± 0.077
Model 0.268 ± 0.010** 0.372 ± 0.006** 0.365 ± 0.017*
XSLJZD 0.417 ± 0.017△△ 0.995 ± 0.088△△ 0.594 ± 0.105△
Low dose XSLJZD 0.372 ± 0.011*△ 0.540 ± 0.050* 0.391 ± 0.012
Domperidone 0.441 ± 0.059△△ 0.824 ± 0.163△△ 0.449 ± 0.046
*P<0.05 compared with the control group; **P<0.01 compared with the control group; ΔP<0.05 compared with the model group; ΔΔP<0.01 compared with the model group
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terms of CCK in the serum (P >0.10); however, the
XSLJZD-treated group exhibited a significant increase in
serum CCK compared with that of rats with FD (82.97 ±
13.47 vs. 22.77 ± 3.59; P = 0.001; n = 7 in each group). VIP
was reduced in the serum of rats with FD (16.95 ± 5.15 vs.
75.61 ± 20.12; P = 0.003; n = 7 in each group) compared
with that in the control group. VIP in the XSLJZD-treated
group significantly increased compared with that in the
model group (62.71 ± 19.05 vs. 16.95 ± 5.15; P = 0.017; n =
7 in each group). No significant difference in VIP of low-
dose XSLJZD-treated groups and domperidone-treated
groups was observed. Nevertheless, a moderate dose of
XSLJZD could increase VIP in the serum (Fig. 11).
XSLJZD increased the gene expression of the relative
neuropeptides in the stomach
In the stomach, the mRNA expressions of ghrelin, CCK
and VIP of rats with FD were lower compared with
those of the control rats (P <0.05; n = 6 in each group).
The mRNA expressions of CCK and VIP of the
XSLJZD-treated group were higher than those of the
model group. No significant difference in ghrelin ex-
pression was observed in the model and drug-treated
groups. Nevertheless, moderate-dose XSLJZD increased
ghrelin mRNA expression in the stomach. In the hypo-
thalamus, the mRNA expressions of ghrelin, CCK and
VIP of rats with FD were higher than those of the
control rats (P <0.05; n = 6 in each group). The mRNA
expression of ghrelin in the XSLJZD-treated and low-
dose XSLJZD-treated groups as well as in the
domperidone-treated group was reduced compared
with that of the model group (P <0.05). CCK mRNA
expression in the low-dose XSLJZD-treated group and
domperidone-treated group was lower (P <0.05) than
that of the model group. Furthermore, VIP mRNA
expression in thedomperidone-treated group was
Fig. 10 Mean integrated optical density (MOD) value of relative neuropeptides. a MOD value of neuropeptides in the stomach. b MOD value of
neuropeptides in hypothalamus. * P <0.05 compared with control group; ** P <0.01 compared with control group. △ P <0.05 compared with the
model group; △△ P <0.01 compared with the model group. Data were presented as mean ± SE
Fig. 11 Expression of relative neuropeptides in the serum. a Expression of Ghrelin of each group. b Expression of CCK of each group. c Expression of
VIP of each group. ** P <0.01 compared with the control group; ΔΔ P <0.01 compared with the model group . Data were presented as mean ± SE
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reduced (P <0.05) compared with that of the model
group. The mRNA expression of these neuropeptides
was not altered in a dose-dependent manner. However,
the mRNA expressions of ghrelin, CCK and VIP in the
hypothalamus of rats with FD were reduced by
XSLJZD (Table 3 and Fig. 12).
Discussion
Our findings demonstrated the mechanism by which the
Chinese medicine XSLJZD relieved FD. Previous studies
revealed that FD is associated with gastric hypersensitivity
to mechanical distention and impaired accommodation
[28, 32]. Gastric hypersensitivity or motor change can be
caused by impairment, such as gastric inflammation or
mechanical impairment, which can occur during childhood;
the change remains, but the impairment was resolved com-
pletely [33, 34]. Previous studies showed that iodoacetami-
decan induce mild damage to the gastric surface and
chronically sensitise gastric sensory afferents during adult-
hood in the absence of overt structural abnormalities. A
rat model displayed the symptoms of functional dyspepsia
similar to that experienced by human beings [28]. There-
fore, iodoacetamide-treated rats as FD model are used to
study the effects and mechanisms of Chinese medicine
XSLJZD.
Studies provided insights into the biological basis of
this form of neonatal programming on the brain–gut
axis [10], and they also demonstrated the release of neu-
ropeptides such as ghrelin, CCK and VIP. Ghrelin, CCK
and VIP are produced in the stomach and then released
into the circulation [14, 20, 25]. The arcuate nucleus
(ARC) of the hypothalamus is implicated in food intake
regulation and energy homeostasis. ARC is adjacent to
the median eminence, which is a ‘circumventricular
organ’ with fenestrated capillaries and an incomplete
blood–brain barrier [35]. Circulating gut hormones can
pass across the median eminence and directly affect the
activity of ARC neurons. The hypothalamus receives
both hormonal signals and peripheral neurons, and then
relay information regarding energy availability [36].
Hormonal signals from the periphery are integrated
with high brain centre signals to regulate appetite and
control energy expenditure. The release of gut hor-
mones, such as ghrelin, CCK and VIP, regulates the
brain–gut axis using hormonal signals [16, 17, 20, 26].
In our study, XSLJZD could increase the food intake
of FD rats. A decrease in sucrose solution consumption
Table 3 The mRNA expression of relative nouropeptides in the stomach and hypothalamus of each group
Part Groups Ghrelin CCK VIP
Stomach Control 1.536 ± 0.509 0.981 ± 0.069 1.092 ± 0.244
Model 0.232 ± 0.172* 0.291 ± 0.121* 0.111 ± 0.059*
XSLJZD 1.735 ± 0.747 1.212 ± 0.320△△ 1.127 ± 0.336△
Low dose XSLJZD 0.439 ± 0.074 0.428 ± 0.125 0.394 ± 0.139
Domperidone 1.797 ± 0.869 0.637 ± 0.095 0.555 ± 0.417
hypothalamus Control 0.967 ± 0.172 1.075 ± 0.268 0.871 ± 0.222
Model 4.917 ± 0.239* 2.923 ± 0.640* 2.084 ± 0.442*
XSLJZD 2.646 ± 0.797△ 2.162 ± 0.511* 0.777 ± 0.295
Low dose XSLJZD 2.804 ± 0.407△ 0.916 ± 0.281△ 1.268 ± 0.285
Domperidone 1.925 ± 0.448△ 1.113 ± 0.247△ 0.617 ± 0.073△
*P <0.05 compared with the control group; ΔP <0.05 compared with the model group; ΔΔP <0.01 compared with the model group
Fig. 12 mRNA expression of neuropeptides in the stomach (a) and hypothalamus (b) of each group. * P <0.05 compared with the control
group; ** P <0.01 compared with the control group; Δ P <0.05 compared with the model group; ΔΔ P <0.01 compared with the model group
by nonparametric test. Data were presented as mean ± SE
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manifests anhedonia, which is the decreased ability to
experience pleasures [30, 37], because of its association
with drink and food intake; this decrease also reflects
the appetite of rats. In our experiment, model rats
showed low percentage of SP value at >75 %; XSLJZD-
induced increase in SP percentage corresponded to the
improvement of the appetite of rats with FD. Early sati-
ation or postprandial fullness or pain in the upper
gastrointestinal origin is the prominent feature observed
in FD patients. Those symptoms in animals are concep-
tually manifested as gastric hypersensitivity to mechan-
ical distention in the absence of overt morphological or
histological changes. In FD patients, the presence of vis-
ceral hypersensitivity to graded gastric distention is pos-
sibly correlated with postprandial pain [38, 39]; other
non-painful symptoms, such as nausea, satiety and full-
ness, are also triggered at lower distension pressures.
This result suggests that multimodal pathways are sen-
sitized [40]. We reproduced this hypersensitivity in our
experiment [28, 32, 41] and calculated the EMG to
graded gastric distention at pressures ranging from
10 mmHg to 50 mmHg. Rats with FD displayed signifi-
cantly higher EMG in response to gastric distention at
20, 30 and 40 mmHg. Our results also showed that
XSLJZD inhibited visceromotor responses caused at dis-
tention pressures of 30 and 40 mmHg. Previous studies
also demonstrated that neonatal IA-treated rats display
significantly higher behavioural scores in response to
gastric distension at 40, 60 and 80 mmHg [28]. In
another study, rats with FD exhibit a significantly higher
EMG in response to gastric distension at 50 mmHg to
120 mmHg with the same result [33]. This difference
may be attributed to the instrument used in this study.
We observed a dose-dependent effect of XSLJZD on
food intake, sucrose preference test and response to
mechanical gastric distension. Low dose elicited slight
or no effect, and XSLJZD caused a more robust effect.
According to the Rome III criteria, epigastric pain or
buming, postprandial fullness and early satiation are
symptoms of FD [42]. XSLJZD could alleviate the main
symptoms of FD in our experiment.
In the experiment, transient gastric irritation in the
neonatal period could result in impaired brain–gut axis
and decrease some neuropeptides. Result manifested the
strong association between FD and the brain–gut axis.
We also examined the effects of transient neonatal gas-
tric inflammation on ghrelin, CCK and VIP expressions;
the brain–gut axis response to stress; and the mechanism
of XSLJZD on FD. The expressions of ghrelin, CCK and
VIP in the stomach and in the serum were significantly
lower in IA-treated rats compared with those in control
rats. These neuropeptides were significantly increased by
XSLJZD. The effect of XSLJZD on the neuropeptides was
dose dependent. In particular, XSLJZD was more effective
than the low dose. The expression of ghrelin, CCK and
VIP were also significantly decreased in the hypothalamus
of rats with FD compared with those of the control rats.
However, the mRNA expressions of these neuropeptides
were increased. XSLJZD increased the protein expression
but decreased the mRNA expression of these neuropep-
tides in the hypothalamus. Ghrelin, CCK and VIP were
produced in the stomach and then released into the blood
[14, 20, 25]. In our experiment, XSLJZD could increase
the production of these neuropeptides, thereby increasing
the neuropeptide levels in circulation. The decrease in the
mRNA expression of these neuropeptides in the hypothal-
amus maybe considered as feedback regulation.
Conclusions
Our results demonstrated that rats with FD with transi-
ent gastric irritation in the neonatal period showed
brain–gut axis impairment and low neuropeptide level.
Chinese medicine XSLJZD could alleviate the symptoms
of FD and upregulate the brain–gut axis by increasing
the production of neuropeptides such as ghrelin, CCK,
and VIP. These findings have major implications in the
mechanism of XSLJZD to relieve FD, which would help
investigate FD mechanism and pharmacokinetics.
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